Osteoarthritis affects 300 million people and is the most common type of arthritis worldwide. It causes severe discomfort, functional limitations, and reduction in activity levels.
The pain and discomfort in knee arthritis varies considerably. Initially, people feel mostly increasing pressure in weight-bearing joints with activities that include, jogging, running, weight training, and going up and down stairs. The pain can become more frequent and the joints unpredictably swell up over the course of time.
Researchers from the University of Boston Medicine and Health (BUSM) and Public Health Universities analysed the Multicenter Osteoarthritis study’s findings on the pain perception of 2 794 older adults with or at risk of knee arthritis in order to explain why this increase in pain expectations takes place. They noticed that people with more pain sensitivity are more likely not only to witness transient pain but to suffer from persistent and unpredictable pain. This research first described a possible underlying mechanism of the nervous system that causes people to feel different patterns of pain with knee arthritis.
With knowledge of multiple pathways that lead to knee arthritis pain, healthcare professionals can now start modifying each patient’s pain management. For instance, treatments that can change the signalling mechanisms of the nervous system can help if a patient has pain sensitization. This strengthens the present ‘one-size-all’ approach, where each patient starts the same treatment and then continues to something else if the first approach does not work.
“By understanding these mechanisms, determining ways to identify those mechanisms in the clinic, and developing treatments to target those mechanisms, we can provide better management options to the millions of people worldwide with osteoarthritis,” said Dr. Neogi.
This is where microfat mesenchymal cell treatments help in alleviating the varying pain experienced by several patients. We use Adipose (fat) derived cell treatments or and platelet-rich plasma which uses autologous cells from Lipoaspirates using the patient’s own adipose tissue to manage the pain signalling factors that govern the degraded joint. These cells carry unique signals called the ‘Anti-inflammatory Cytokines’ or “good” proteins (IL-1ra, sIL-1R, sTNF-RI and sTNF-RII). These were seen after obtaining the right concoction of lipoaspirate cells with platelet-rich plasma. These proteins were found to block the inflammatory cytokines or “bad” proteins (IL-1 and TNF) that initiate pain and cartilage degeneration. 98% of the patients in a recent study (Woodel et.al, 2014) showed an increased number of anti-inflammatory proteins were obtained in injectables. This study significantly shows that the solution contained from the blood of osteoarthritic patients contains healing factors in order to outnumber the inflammatory proteins that cause knee pain, stiffness, and degeneration.
Carlesso, L.C., et al. (2020) The Association of Pain Sensitization and Conditioned Pain Modulation to Pain Patterns in Knee Osteoarthritis. Arthritis Care & Research. doi.org/10.1002/acr.24437.
Autologous Protein Solution prepared from blood of Osteoarthritic Patients, contain an enhanced profile of anti-inflammatory cytokines and anabolic growth factors. – Journal of Orthopaedic Research. 2014 By: Woodell-May J, Matuska A, Oyster M, Welch Z, O’Shaughnessey K, Hoeppner J.